ClinicalTrials.Veeva

Menu

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Pfizer logo

Pfizer

Status and phase

Completed
Phase 3

Conditions

Breast Neoplasms

Treatments

Drug: exemestane
Drug: anastrozole

Study type

Interventional

Funder types

Industry

Identifiers

NCT00143390
A5991048

Details and patient eligibility

About

To verify the non-inferiority of exemestane compared to anastrozole in time to tumor progression (TTP), the primary efficacy endpoint, in postmenopausal women with advanced/recurrent breast cancer.

Enrollment

298 patients

Sex

Female

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have histologically or cytologically confirmed breast cancer at original diagnosis. At study entry, the patient must have metastatic progressive or locally recurrent inoperable breast cancer.

Exclusion criteria

  • Having received any hormonal therapy (e.g., Tamoxifen, LHRH-agonists) ovariectomy or any chemotherapy for advanced/recurrent breast cancer

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

298 participants in 2 patient groups

1
Experimental group
Treatment:
Drug: exemestane
2
Experimental group
Treatment:
Drug: anastrozole

Trial contacts and locations

46

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems